D amperidone Drotaverine | No-shpa tablets 40 mg 24 pcs.

packaging 24 pcs

Pharmacological action

No-spa - antispasmodic myotropic action.

Reduces the tone of the smooth muscles of internal organs, reduces their motor activity, moderately dilates blood vessels.

In severity and duration of antispasmodic action surpasses papaverine. It does not affect the autonomic nervous system and central nervous system.

Due to the fact that No-spa acts directly on smooth muscle, it can be used as an antispasmodic in cases where medicines from the group of anticholinergics are contraindicated (glaucoma, prostatic hypertrophy).

Indications

smooth muscle spasms associated with diseases of the biliary tract (cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis)

smooth muscle spasms of the urinary tract, nephritis, pyrolithiasis, nephrolithiasis, nephrolithiasis, nerolithiasis, pyrolithitis.

As adjuvant therapy:

for spasms of smooth muscles of gastrointestinal origin (peptic ulcer of the stomach and duodenum, gastritis, spasms of the cardia and pylorus, enteritis, colitis, spastic colitis with constipation and meteoric forms of mucous colitis)

headaches of the tensile type

for gynecological diseases (dysmenorrhea).

Contraindications

Severe renal or hepatic insufficiency.

severe heart failure (low cardiac output syndrome).

hypersensitivity to drotaverine or to any excipient of the

preparation for children under 1 year of age.

lactose deficiency.

galactosemia or impaired glucose / galactose absorption syndrome.

Caution: arterial hypotension.

Use in pregnancy and lactation

As reproductive studies in animals and retrospective studies of clinical data have shown, the use of drotaverine during pregnancy did not have either teratogenic or embryotoxic effects. Despite this, when using the drug during pregnancy, the potential benefits for the mother and the possible risk to the fetus should be correlated.

In the absence of the necessary clinical data during lactation is not recommended.

Composition

1 tablet contains drotaverin hydrochloride 40 mg

Dosage and administration

Adults are prescribed 1-2 tablets. 3 times / day

Children. Clinical studies using drotaverine involving children have not been conducted.

In case of prescribing drotaverine to children:

for children 6-12 years old, the maximum daily dose is 80 mg, divided into 2 doses.

for children over 12 years of age, the maximum daily dose is 160 mg, divided into 2–4 doses.

Side effects

gastrointestinal disturbances (rarely - nausea, constipation)

nervous system disorders (rarely - headache, dizziness, insomnia)

cardiovascular disorders (rarely - heart palpitations, very rarely - hypotension) srdlp (very rarely - allergic reactions, especially in patients with increased sensitivity to bisulfites).

Drug Interaction

Caution should be exercised when co-administered with levodopa, since the antiparkinsonian effect of the latter decreases and there is an increase in tremor and rigidity.

Overdose

Symptoms: heart rhythm and conduction abnormalities, including complete blockage of the GIS bundle legs and cardiac arrest, which can be fatal.

Treatment: in the event of an overdose, patients should be medically monitored and, if necessary, should be treated symptomatically and aimed at maintaining the essential functions of the body, including the induction of vomiting or gastric lavage.

Storage conditions

At a temperature not exceeding 25 РC.

The Expiration of

is 5 years.

Deystvuyuschee substances

Drotaverine



pharmacy terms and conditions without a prescription

Quinoin Plant of Pharmaceutical and Chemical Products, engriya